Clinical trials: Yellow Fever
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
The study is designed as a Phase III, double-blind, multi-center, randomized, active-controlled study in which four groups of participants (n=554 per group) will receive either one of three different manufacturing lots of SII-YFV…
- Trial name
- NCT05447377
- Testing
- SII Yellow Fever Vaccine, STAMARIL®
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 2,216 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Yellow Fever
Trial of an Inactivated Yellow Fever Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 1 mcg and 5 mcg of HydroVax-002 YFV vaccine given intramuscularly on Day 1 and Day 29…
- Trial name
- NCT05172544
- Testing
- HydroVax-002 YFV
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Yellow Fever
Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia
VYF03 is a phase II, randomized, parallel-group prevention study with 2 arms, active-controlled (Stamaril), observer-blind, multi-center study to assess the non-inferiority of the immune response, in terms of seroconversion rates…
- Trial name
- NCT05011123
- Testing
- Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
- Where
- 23 sites in Finland, France and 4 more
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever, Encephalitis, Japanese
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
Epidemic viral diseases have become more prevalent in recent years. Among the various strategies to prevent such epidemics, vaccination is the most cost-effective.
- Trial name
- NCT01943305
- Testing
- Japanese Encephalitis vaccine, Yellow Fever vaccine
- Where
- Singapore
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Rheumatic, Dermatologic Disorders
Yellow Fever Vaccination Under Low Dose Methotrexate Therapy
Travelers (n = 30, 15 taking low-dose methotrexate (MTX), 15 healthy controls (HC), seeking travel advice in one of the following Swiss Travel Centers (Aarau, Basel, Bern, Geneva, Lausanne, Zurich) and who have an indication for…
- Trial name
- MTX_YF (NCT02383680)
- Testing
- Yellow Fever Vaccination
- Where
- 6 sites in Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Yellow Fever
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea
This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.
- Trial name
- NCT03541694
- Testing
- Stamaril®
- Where
- South Korea
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever, Healthy Volunteers
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the…
- Trial name
- VYF02 (NCT04942210)
- Testing
- Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine
- Where
- 11 sites in United States
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Yellow Fever
A Pilot Study to Finetune Skin Processing Procedures in Recent Vaccinees, Prior to GeKoSkimm Study Initiation (GeKoSkimm-pilot)
This pilot study aims to optimize the sample processing techniques for collecting and analyzing skin biopsies obtained from individuals routinely vaccinated against yellow fever.
- Trial name
- NCT06539351
- Testing
- Skin biopsy
- Where
- Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Yellow Fever
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
The study is designed as a Phase III, double-blind, multicenter, randomized, active-controlled, parallel-group design in which two groups of participants will receive either SII-YFV or STAMARIL® - a licensed and WHO pre-qualified…
- Trial name
- NCT05421611
- Testing
- STAMARIL, SII-YFV
- Where
- 2 sites in Kenya
- Volunteers
- 1,824 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Yellow Fever Immunization
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and…
- Trial name
- NCT07103148
- Testing
- Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated
- Where
- 15 sites in Honduras, Mexico and 1 more
- Volunteers
- 2,440 people, healthy volunteers welcome
- Sponsor
- Sanofi
Meningococcal Disease, Meningococcal Meningitis
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Typhoid, Yellow Fever
- Trial name
- NCT01466387
- Testing
- Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine
- Where
- 5 sites in Czechia, Germany
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- Novartis
Infectious Disease, Yellow Fever
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
We hypothesize that a high CD4+ and CD8+ T cell count will reduce viremia upon challenge with a structurally heterologous virus, and correspondingly result in reduced magnitude of host response to challenge infection.
- Conditions
- Infectious Disease, Yellow Fever, Japanese Encephalitis, Viral Infection
- Trial name
- NCT05568953
- Testing
- Stamaril, Imojev, Ixiaro
- Where
- Singapore
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Yellow Fever
Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults
The investigators at Rockefeller University are doing this research to study how the immune system responds to viruses and other infectious agents by using the yellow fever 17D vaccine as a model.
- Trial name
- NCT00616356
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Dengue, Dengue Fever
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01488890
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
- Where
- 7 sites in United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Vaccination
The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination
This study aims to investigate the effect of providing additional information about possible mild side effects of the yellow fever vaccination on the reporting of physical symptoms.
- Trial name
- NCT00708630
- Testing
- Extended information on side effects
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Auckland, New Zealand
Vaccine Response Impaired
Antibiotics and Vaccine Immune Responses Study
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
- Trial name
- AVIRS (NCT06148025)
- Testing
- BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule
- Where
- Australia
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- South Australian Health and Medical Research Institute
Healthy
Yellow Fever Immune Response at Single Cell Resolution
The immune system is composed of diverse cell types with different functions that act together in order to defend against infection.
- Trial name
- NCT03458780
- Testing
- Yellow Fever Vaccine
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Yellow Fever
The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses.
- Trial name
- NCT04269265
- Testing
- Yellow Fever Vaccine
- Where
- 2 sites in United States, Uganda
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Yellow Fever Immunization
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years.
- Trial name
- NCT07002060
- Testing
- Yellow fever vaccine (live), YF vaccine (live)
- Where
- 7 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sanofi
Yellow Fever
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
A randomized clinical trial comparing fractional dose Yellow Fever vaccination to the full dose among children aged 9-23 months in Uganda.
- Trial name
- NCT03725618
- Testing
- Yellow Fever 17DD Vaccine
- Where
- United States
- Volunteers
- 1,788 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention